biomea fusion
Mini Balakrishnan serves as Executive Director at Biomea Fusion since September 2021, focusing on targeted therapies using covalent small molecule inhibitors for oncology and diabetes. In this role, Mini leads preclinical efforts to bolster Biomea’s Discovery and Development pipelines. Prior to this position, Mini held various roles at Gilead Sciences from November 2006 to April 2021, progressing from Research Scientist II to Principal Scientist. Mini also served as Research Assistant Professor at the University of Rochester Medical Center from 2002 to 2006, conducting research on HIV-1 reverse transcriptase and RNase H to investigate viral replication. Early research experience includes a role as Research Assistant at OCCaP, Indian Institute of Science, Bangalore. Educational qualifications include a Ph.D. in Molecular Biology from New Mexico State University and an M.Sc. in Biotechnology from Cochin University of Science and Technology, complemented by postdoctoral research at the University of Rochester School of Medicine and Dentistry.
biomea fusion
Biomea Fusion, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was formed in 2017 by a small group of biotech executives that came together with the common goal of achieving better therapies for patients.